The Tachi Yamada legacy tree continues to grow with a new gene editing biotech from Jim Wilson
Jim Wilson has been busy lately.
Back in May, the AAV pioneer from the University of Pennsylvania launched a second-generation gene therapy biotech, G2 Bio Companies, and just last week unveiled a nonprofit aiming to serve rare disease populations where the pharma model provides little economic incentive. Both efforts saw significant involvement from the late Tachi Yamada, who continues to inspire those working at his legacy startups.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.